Staff Directory Contact Us

The Nathan S. Kline Institute for Psychiatric Research

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects with Autism Spectrum Disorder

The primary objective of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of ASD during 12 weeks of treatment.

Study Length: 
Approximately 4 months
Disorder/Condition: 
Autism Spectrum Disorder
Inclusion Criteria: 

Males and Females, ages 13-35 with ASD

Study Title (brief): 
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects with Autism Spectrum Disorder
Study Description (brief): 

The primary objective of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of ASD during 12 weeks of treatment.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org.